Kensey Nash (KNSY) Receives FDA Clearance for its First Extracellular Matrix Product, Medeor
More News related to KNSY
- Kensey Nash (KNSY) Receives FDA Clearance for its First Extracellular Matrix Product, Medeor
- Kensey Nash Receives FDA 510(k) Clearance for Porcine Dermis Biologic Product
- Kensey Nash (KNSY) Posts Q1 EPS of $0.43; GUides
- Kensey Nash Reports First Quarter Fiscal Year 2010 Financial Results
- Trading Radar for 10/22: AT&T (T), McDonalds (MCD), Amazon.com (AMZN), 3M (MMM), Dow Chemical (DOW), UPS (UPS) Report
More News related to FDA
- Cornerstone Therapeutics (CRTX) Receives Warning Letter From FDA
- Pfizer (PFE) Gets Okay for Bipolar Treatment Geodon from U.S. FDA
- Intuitive Surgical (ISRG) Receives Japanese Approval for da Vinci
- Dendreon Corp. (DNDN) Receives U.S. FDA Complete Response for PROVENGE CRPC Treatment
- Boston Scientific (BSX) Receives 510(k) Clearance and CE Mark on WallFlex
Kensey Nash Corporation (Nasdaq: KNSY) announced that it has received 510(k) clearance for its first extracellular matrix (ECM) product, Medeor(TM) Matrix, from the U.S. Food and Drug Administration. The clearance allows for the use of Medeor Matrix in general surgery for the reinforcement and repair of soft tissue, including hernia repair and plastic and reconstructive surgical applications.
Medeor Matrix is a porcine-based dermal extracellular matrix designed to act as a biologic scaffold to stimulate the deposition of organized tissues specific to an injured site. These ECM products facilitate rapid revascularization and are therefore quickly repopulated with cells from the host tissue and ultimately converted into functional living tissue. Medeor Matrix is manufactured using Kensey Nash's proprietary Optrix(TM) process, which gently disinfects tissues, inactivates viruses and removes cells while preserving extracellular matrix components.
[SM]
Related Categories
FDAStocks Mentioned
+0.10Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
